



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting
February 21, 2018**

NOTE: Unless the information is confidential, the reports and presentations referenced in the minutes are available at http://www.cprit.state.tx.us/cprit-media/oc_packet_02-21-2018.pdf. Information regarding the recommended awards is available at http://www.cprit.state.tx.us/cprit-media/proposed_grant_awards_book_02212018.pdf.

Call to Order – Agenda Item 1

A quorum being present, Presiding Officer Will Montgomery called the Oversight Committee to order at 10:02 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Amy Mitchell
Angelos Angelou
Bill Rice, M.D.
Donald (Dee) Margo
Will Montgomery

Mahendra Patel, M.D. was not present at roll call. Dr. Patel arrived at 10:09 a.m. as noted in the minutes.

Absent

Craig Rosenfeld, M.D.

MOTION:

On a motion by Mr. Margo and seconded by Mr. Angelou, the Oversight Committee unanimously voted to excuse the absence of Dr. Rosenfeld.

Adoption of Minutes from the November 29, 2017 and January 17, 2018 Meeting – Agenda Item 3 – Tab 1

MOTION:

On a motion by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the minutes of the Oversight Committee meetings of November 29, 2017 and January 17, 2018, as presented.

Public Comment – Agenda Item 4

Presiding Officer Montgomery noted that there were three requests for public comment.

Mr. Cam Scott, Senior Director of Texas Government Relations for the American Cancer Society Cancer Action Network, provided a handout (included in the Oversight Committee packet). He reported that the American Cancer Society (ACS) wants CPRIT to continue and requested that CPRIT submit a legislative appropriations request that includes an exceptional item for additional funding to keep grant funding at current levels in the FY 2020-2021 biennium. Mr. Scott spoke to CPRIT's important work and that ACS will continue to do what they can to see CPRIT continue.

Mr. Robert Sartin, an ACS volunteer, shared that doctors diagnosed his son, Spencer, with acute lymphocytic leukemia when Spencer was four years old. He is now 18. Mr. Sartin believes that his son would not be here if he had not been part of a research study in 1991, which helped refine the treatment protocol and reduce the length of chemotherapy. Mr. Sartin and Spencer were guests of their state representative and attended the State of the State Address when Governor Perry proposed CPRIT. He encouraged the Oversight Committee to act to continue funding for CPRIT without interruption.

Mr. Jason Chilton, a volunteer with Young Texans Against Cancer (YTAC) of Austin, said that one of the greatest functions of government is to protect the lives of its citizens. Cancer takes the lives of more citizens than the tragedies we see in the news every day. He supports the legislature providing continued funding to create a greater impact and to help Texans move closer to a cure.

There were no questions regarding the public comments. Presiding Officer Montgomery thanked Mr. Scott, Mr. Sartin, and Mr. Chilton for their comments.

Presiding Officer Montgomery noted for the record that Dr. Patel arrived at 10:09 a.m.

Grantee Presentation – Agenda Item 5 – Tab 2

Michael Lang, Chief Product Development Officer, introduced Dr. Gary Latham, Sr. Vice President of Research and Development at Asuragen. Asuragen is a molecular diagnostic company located in Austin. Molecular diagnostics play a critical role in the assessment of cancer. Asuragen is one of CPRIT's early awardees, receiving a \$6.8 million grant in 2012.

Dr. Latham reported on the next-generation sequencing diagnostic tool that Asuragen developed with the support of a CPRIT grant award. Asuragen markets the tool currently. Dr. Latham noted that the CPRIT grant award resulted in many lasting and positive follow-on effects for the company. For example, he said that the cancer diagnostic tool developed with support from CPRIT resulted in a major industry partnership. The industry partnership led Asuragen to upgrade their laboratory facilities, which fueled the company's decision to remain in Texas for the long term. Dr. Latham also discussed a collaboration with MD Anderson, spurred by the CPRIT grant, which utilized Asuragen's tool to design targeted therapies for cancer patients in the BATTLE-2 Program.

Dr. Latham replied to an Oversight Committee member's question about how widely used the Asuragen tool was, explaining that the company distributes these products globally. He reports that Asuragen has a global footprint with a distribution network of more than 60 countries.

An Oversight Committee member inquired about Dr. Latham's views on the diagnostic potential of protein-expression and protein-protein interactions. Dr. Latham replied that he sees exciting potential in the use of proteins in addition to DNA and RNA.

Presiding Officer Montgomery thanked Dr. Latham and Asuragen's team for their work and presentation to the Oversight Committee.

Chief Executive Officer Report – Agenda Item 6 – Tab 3

Presiding Officer Montgomery recognized Mr. Wayne Roberts to provide the CEO report.

Mr. Roberts noted that if the Oversight Committee approves all recommendations presented at the meeting, there will be \$199 million in available grant funds for the rest of the year.

Mr. Roberts presented his report on grant progress as required by Texas Health & Safety Code § 102.260(c). He explained that FY 2017 was another year of progress for CPRIT and its three programs. Key metrics indicate that CPRIT is affecting Texas' national standing in both cancer research and the biomedical industry. Mr. Roberts directed the Oversight Committee members to page 3-22 of their packet for the breakdown of each program.

There were no questions for Mr. Roberts.

Chief Compliance Officer Report – Agenda Item 7 – Tab 4

Mr. Vince Burgess, Chief Compliance Officer, presented his certification report (in the meeting packet at 4-1) on the status of required grantee reports, financial status report reviews, desk reviews and site visits, annual compliance attestation, single audit tracking, and training.

Mr. Burgess noted that CPRIT has scheduled a grantee training webinar for March 7, 2018. The training will cover grant reporting requirements, administrative rule changes, grant closeout, and an overview of the compliance program. The Compliance Program plans two training webinars in June and October of 2018.

Mr. Burgess directed Oversight Committee members to page 4-3 in their agenda packet, reporting that the number of delinquent grantee reports has increased this month. He indicated that 11 grantees did not file 38 required reports by the due date. Mr. Burgess attributed the increase to a change in the sequencing of the Matching Compliance Certification form; of the 38 late reports, 32 reports are the Matching Compliance Certification forms. CPRIT now requires grantees to submit forms in a specific order and only after CPRIT approves the previous form may the grantee submit the next form. Of the 32 delinquent matching compliance forms, 90% were from two grantees. CPRIT has an on-going bi-weekly call with one of these grantees and has instituted a bi-weekly call with the other grantee to provide additional assistance.

An Oversight Committee member inquired about the balance between compliance and productivity. Mr. Burgess replied that the compliance program continues to work at striking an appropriate a balance.

Chief Scientific Officer Report, Grant Award Recommendations, and Request for Applications FY 2019 – Agenda Item 8 – Tab 5

Academic Research Award Recommendations

Presiding Officer Montgomery recognized Dr. Jim Willson, Chief Scientific Officer, to present the academic research award slates recommended by the CPRIT Scientific Review Council (SRC) and the Program Integration Committee (PIC). Dr. Willson indicated that the SRC and the PIC recommended 44 Individual Investigator and five Recruitment awards totaling \$60,195,197.

Dr. Willson provided a high-level overview of the recommended Individual Investigator Research Awards (IIRA) by the five IIRA mechanisms, noting an overall success rate of 8.6% (521 applications submitted/ 44 awards recommended).

In response to an Oversight Committee member's question regarding the computational biology slate success rate, Dr. Willson responded that CPRIT provides written feedback to the applicants regarding the strengths and weaknesses of their applications. This feedback can help the applicant if he or she decides to reapply.

Dr. Willson presented five recruitment grant awards recommended by the SRC and the PIC. He provided a brief introduction of the five candidates for Recruitment of Rising Stars and Recruitment of First-Time Tenure Track Faculty Member mechanisms, totaling \$14,000,000.

Compliance Certification (Academic Research and Prevention Awards)

Mr. Burgess presented his certification of the review process for the proposed grant awards recommended to the Oversight Committee (included in the meeting packet). He reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the seven academic research award mechanisms and four prevention award mechanisms.

Conflict of Interest Notification

Presiding Officer Montgomery noted that Mr. Angelou reported a conflict of interest with three applications submitted by The University of Texas at Austin, grant applications RP18073, RP180381, and RP180590.

Presiding Officer Montgomery suggested that, unless a member objected, the Oversight Committee consider all the academic research award recommendations together in one vote except for the proposed awards to The University of Texas at Austin, which the committee would vote on separately. No member objected.

ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
RP180313	IIRA	1.0	A somatic mutant p53 mouse model of metastatic triple negative breast cancer	Lozano, G.	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP180505	IIRAP	1.4	Circulating Exosomes as Biomarkers for Lung Cancer Early Detection	Taguchi, A.	The University of Texas M. D. Anderson Cancer Center	\$799,085
RP180147	IIRA	1.6	Prevalence of Rare Passenger Mutations in Biopsy Tissue as Cancer Stratification Markers	Zhang, D.	Rice University	\$900,000
RP180047	IIRA	1.7	A Novel Dual Suppressor of Cancer Bone Metastasis	Wan, Y.	The University of Texas Southwestern Medical Center	\$898,672
RP180192	IIRA	1.8	Dissecting the interplay between BAP1 and PBRM1 in renal cancer	Brugarolas, J.	The University of Texas Southwestern Medical Center	\$897,633
RP180343	IIRA	1.8	Turn ON the Tumor Contrast in Lymph Node Metastases for Occult Disease Detection	Gao, J.	The University of Texas Southwestern Medical Center	\$885,684
RP180178	IIRA	1.8	Imaging glucose stimulated zinc secretion (GSZS) from the prostate by MRI: A potentially powerful method for early detection of prostate cancer	Sherry, D.	The University of Texas Southwestern Medical Center	\$900,000
RP180463	IIRACCA	1.9	Compound heterozygous mutations in pediatric cancer predisposition	Schlacher, K.	The University of Texas M. D. Anderson Cancer Center	\$556,763*
RP180248	IIRACB	1.9	Characterizing cancer genome instability and translational impact using new sequencing technologies	Chen, K.	The University of Texas M. D. Anderson Cancer Center	\$898,997
RP180191	IIRACCA	1.9	Understanding TFE3-mediated Tumorigenesis through Analysis of a Novel, Clinically-Relevant Mouse Model of Translocation Renal Cell Carcinoma	Brugarolas, J.	The University of Texas Southwestern Medical Center	\$1,155,128
RP180220	IIRA	1.9	Targeting the prion protein Doppel in brain tumor angiogenesis	McCarty, J.	The University of Texas M. D.	\$900,000

ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
					Anderson Cancer Center	
RP180435	IIRA	2.0	Fasting-induced inhibition of leukemia development	Zhang, C.	The University of Texas Southwestern Medical Center	\$900,000
RP180275	IIRA	2.0	Targeting Stromal ERalpha for Cervical Cancer Therapy	Chung, S.	University of Houston	\$811,617
RP180381	IIRACT	2.0	Mass Spectrometry Imaging to Uncover Predictive Metabolic Markers of Ovarian Cancer Surgical Outcome and Treatment Response	Schiavinato Eberlin, L.	The University of Texas at Austin	\$1,092,048
RP180394	IIRACCA	2.0	Targeting the metastatic sarcoma niche using leukocyte biomimetic nanoparticles	Tasciotti, E.	The Methodist Hospital Research Institute	\$1,199,617
RP180131	IIRACCA	2.1	DNA methylation signatures of cell-free DNA in CSF as a new response biomarker for pediatric medulloblastoma	Sun, D.	Texas A&M University System Health Science Center	\$1,200,000
RP180196	IIRACCA	2.1	Microwafers as Novel Drug or Gene Delivery Vehicles for Noninvasive Treatment of Retinoblastoma	Hurwitz, R.	Baylor College of Medicine	\$1,195,721
RP180410	IIRA	2.2	Mechanisms of Nuclear Export in Cancer	Chook, Y.	The University of Texas Southwestern Medical Center	\$900,000
RP180181	IIRA	2.2	Targeting neutrophil elastase as a novel therapy for metastatic breast cancer	Watowich, S.	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP180504	IIRA	2.2	Elucidating the Epigenetic and Metabolic Vulnerabilities of Myeloproliferative Neoplasms	Xu, J.	The University of Texas Southwestern Medical Center	\$900,000
RP180268	IIRA	2.2	Determining the role of polyploidization in liver cancer development	Zhu, H.	The University of Texas Southwestern Medical Center	\$900,000
RP180309	IIRA	2.2	Inhibiting Oxidative Phosphorylation: A Novel Strategy in Leukemia	Konopleva, M.	The University of Texas M. D. Anderson Cancer Center	\$900,000

ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
RP180261	IIRA	2.2	Multi-Loading Strategy for Constructing Potent Antibody-Drug Conjugates	Tsuchikama, K.	The University of Texas Health Science Center at Houston	\$900,000
RP180473	IIRACT	2.2	Clinical trials of C188-9, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with hepatocellular carcinoma (HCC)	Tweardy, D.	The University of Texas M. D. Anderson Cancer Center	\$2,399,905
RP180031	IIRA	2.2	Imaging of biochemical alterations in human breast malignancy using CEST-MRI	Vinogradov, E.	The University of Texas Southwestern Medical Center	\$900,000
RP180244	IIRA	2.3	Functional analyses of linkage-specific ubiquitination in the DNA damage response	Wang, B.	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP180404	IIRACT	2.3	Noninvasive detection of anthracycline induced cardiotoxicity using hyperpolarized carbon 13 based magnetic resonance spectroscopic imaging	Zaha, V.	The University of Texas Southwestern Medical Center	\$2,397,204
RP180349	IIRA	2.4	Therapeutics Targeting Cancer-Associated HPV Replication	Chiang, C.	The University of Texas Southwestern Medical Center	\$900,000
RP180530	IIRA	2.4	Hippo signaling in non-alcoholic fatty liver disease (NAFLD) and its progression to hepatocellular carcinoma	Johnson, R.	The University of Texas M. D. Anderson Cancer Center	\$821,669
RP180607	IIRAP	2.4	Blood-based biomarkers for the early detection of pancreatic cancer	Killary, A.	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP180590	IIRA	2.4	Development of an engineered & pharmacologically optimized human methionine-gamma-lyase drug candidate for the treatment of prostate cancer and glioblastoma	Stone, E.	The University of Texas at Austin	\$900,000
RP180553	IIRA	2.5	Structural and Functional Characterization of the DNA Double Strand Break Processing Complex of Mre11-Rad50	Latham, M.	Texas Tech University	\$850,876

ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
RP180259	IIRA	2.5	PTEN Promotes Diabetic breast cancer metastasis	LIN, C.	The University of Texas M. D. Anderson Cancer Center	\$900,000
RP180588	IIRAP	2.5	Novel Computer Aided Diagnosis System For Early Detection Of Oral Cancer Based On Quantitative Autofluorescence Imaging	Jo, J.	Texas Engineering Experiment Station	\$897,394
RP180166	IIRACCA	2.6	Molecular mechanisms of anthracycline response in cardiomyocytes and link to genetic susceptibility to cardiotoxicity in long-term childhood cancer survivors	Hildebrandt, M.	The University of Texas M. D. Anderson Cancer Center	\$1,194,520
RP180466	IIRACT	2.6	Integrated single-cell biomarkers of T-cell efficacy	Varadarajan, N.	University of Houston	\$1,173,420
RP180055	IIRA	2.7	Mechanisms and Treatment of Hippocampal Cognitive Impairment Associated with Androgen Deprivation Therapy for Prostate Cancer	Morilak, D.	The University of Texas Health Science Center at San Antonio	\$899,547
RP180472	IIRA	2.8	Mucosal vaccine formulations for targeted therapy of HPV cancers	Sastry, J.	The University of Texas M. D. Anderson Cancer Center	\$883,146
RP180457	IIRA	2.8	Tumor Activated Enzyme Inhibitors for the Treatment of Cancer	Ready, J.	The University of Texas Southwestern Medical Center	\$898,776
RP180140	IIRACT	2.8	EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial to assess local control of oligometastatic disease	Tang, C.	The University of Texas M. D. Anderson Cancer Center	\$2,394,412
RP180634	IIRACCA	2.9	Understanding metabolic regulation of pediatric glioma through mouse modeling and patient tumor interrogation in vivo.	Bachoo, R.	The University of Texas Southwestern Medical Center	\$1,200,000
RP180073	IIRACCA	3.4	Myeloid support of refractory and aggressive T-ALL at distinct tumor sites	Ehrlich, L.	The University of Texas at Austin	\$1,200,000
RP180177	IIRA	3.5	Novel Small Molecule Probes Targeting Histone Acetyltransferase p300/CBP	Song, Y.	Baylor College of Medicine	\$900,000

ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
RP180288	IIRA	3.5	Innate Immune Regulation of Cancer Cell Proliferation	Yan, N.	The University of Texas Southwestern Medical Center	\$900,000
RP180319	IIRACCA	3.5	Rhabdomyosarcoma vulnerabilities: Prioritizing and extending to the clinic	Skapek, S.	The University of Texas Southwestern Medical Center	\$1,193,363

*RP180463 reflects budget as reduced by the SRC. SRC recommended to fund only Aim 1 and reduce the duration of the study from 4 years to 3.

Academic Research Recruitment Grant Awards					
App ID	Mechanism	Candidate	Organization	Budget	Overall Score
RR180011	RFTFM	Bose, Rohit	The University of Texas M.D. Anderson Cancer Center	\$2,000,000	1.0
RR180014	RFTFM	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
RR180017	RFTFM	Jiang, Wen	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
RR180016	RRS	Hoshida, Yujn	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
RR180012	RRS	Jiang, Xiaoqian	The University of Texas Health Science Center at Houston	\$4,000,000	2.8

RRS: Recruitment of Rising Stars RFTFM: Recruitment of First-Time Tenure Track Faculty Members

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the PIC’s recommendations for The University of Texas at Austin grant applications RP180073, RP180381, and RP180590.

Presiding Officer Montgomery noted for the record that Mr. Angelou did not vote on these recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the PIC’s recommendations for the remaining 46 academic research awards.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff and authorized the Chief Executive Officer to sign the contracts on behalf of CPRIT.

Academic Research Program Report

Dr. Willson presented his report (page 5-1 – 5-5 in the agenda packet).

In response to an Oversight Committee member's question, Dr. Willson explained that the academic research program maintains a master list of CPRIT Scholars recruited to Texas, which includes the state and institution of Origin. Mr. Wayne Roberts also noted that the quarterly Achievement Report provides a high-level view of this information.

Proposed Plan for RFAs for FY 2019 Cycle 2

Dr. Willson presented the FY 2019 RFA release schedule (page 5-5) for consideration. The proposed RFAs in the schedule include: Recruitment of Established Investigator, Recruitment of Rising Stars, Recruitment of First-Time Tenure Track Faculty Members, Core Facilities Support Awards, High Impact/High Risk Research Awards, and Early Translation Research Awards.

MOTION:

On a motion made by Dr. Patel and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the Academic Research Program's plan for proposed RFAs for the second cycle of FY 2019.

Chief Prevention and Communications Officer Report, Grant Award Recommendations, and Request for Applications FY 2019 – Agenda Item 9 – Tab 6

Prevention Award Recommendations

Presiding Officer Montgomery recognized Dr. Rebecca Garcia, Chief Prevention and Communications Officer, to present the Prevention Review Council (PRC) and PIC's recommendations for prevention awards. She reported that the PRC and PIC recommended eight projects, representing four grant mechanisms totaling \$13,105,573. Dr. Garcia noted that the PIC agreed with the PRC's recommendation to reduce the budgets of PP170078 and PP170121, deferred from Cycle 17.2, by ten percent. Dr. Garcia reported that all the recommended applications address one or more of the Prevention Program priorities.

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP170121 Deferred from 17.2	EBP	Evidence-Based Hepatocellular Cancer Prevention through Target Hepatitis C Screening and Navigation	Jain, Mamta	The University of Texas Southwestern Medical Center	1.3	1	\$1,300,994
PP180003	EBP	BEST 2: Breast Cancer Education Screening and Navigation (BEST) Program for El Paso and West Texas	Shokar, Navkiran K	Texas Tech University Health Science Center at El Paso	1.7	2	\$1,499,908

PP180031	EBP	Get FIT to Stay Fit. Stepping Up to Fight Colorectal Cancer in the Panhandle.	Obokhare, Izi D	Texas Tech University Health Science Center	1.8	3	\$1,498,476
PP180016	TCL	Equitable Access to Lung Cancer Screening and Smoking Cessation Treatment: A Comprehensive Primary Care and Community Health Approach	Zoorob, Roger	Baylor College of Medicine	2	4	\$1,472,918
PP170078 Deferred from 17.2	CRC	Alliance for Colorectal Cancer Testing 2.0 (ACT 2.0)	Foxhall, Lewis E	The University of Texas M. D. Anderson Cancer Center	3.1	5	\$4,034,507
PP180025	TCL	Lung Cancer Screening and Patient Navigation (LSPAN)	Argenbright, Keith E	The University of Texas Southwestern Medical Center	3.3	6	\$1,499,997
PP180037	EBP	Advancing an Established Colorectal Cancer Prevention Program for Rural and Underserved Texans through A&M's Family Medicine Residency	McClellan, David A	Texas A&M University System Health Science Center	3.3	7	\$1,499,202

Prevention Grant Award Recommendations – Dissemination Cycle 18.2

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP180065	DI	Disseminating Cancer Control Framework and Strategies, a UT System Partnership	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.3	1	\$299,571

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

Dr. Garcia responded to Oversight Committee members' questions, explaining that the 42 counties in the Colorectal Cancer Testing 2.0 Coalition project are not contiguous but are spread throughout the state and that the statewide colorectal cancer coalition meets annually but there is subcommittee activity throughout the year.

Dr. Garcia directed the Oversight Committee members to the "Counties of Residence of Populations Served by CPRIT Prevention Projects" map on page 80a in their award packets. The map includes sixty-six active and proposed projects and noted that CPRIT grantees have provided more than 4.3 million prevention services across the state. An Oversight Committee member commended the prevention program and grantees for providing services to residents of all Texas counties.

Compliance Certification

Presiding Officer Montgomery noted that Mr. Burgess previously certified compliance of the prevention awards process.

Conflict of Interest Notification

Presiding Officer Montgomery noted that no Oversight Committee member reported a conflict of interest with the applications under consideration.

Presiding Officer Montgomery suggested that, unless a member objected, the Oversight Committee consider all the prevention recommendations in one vote. No member objected.

MOTION:

On a motion made by Mr. Angelou and seconded by Ms. Mitchell, the Oversight Committee unanimously voted to approve the PIC's recommendations for Tobacco Control and Lung Cancer Screening, Colorectal Cancer Prevention Coalition, Evidence-Based Cancer Prevention Services, and Dissemination of CPRIT-Funded Cancer Control Intervention awards.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff and authorized the Chief Executive Officer to sign the contracts on behalf of CPRIT.

Proposed Prevention RFAs FY 2019 Cycle 1

Dr. Garcia directed members to pages 6-1 – 6-3 in their meeting packets and discussed the proposed RFAs and timeline for the prevention awards in the first cycle of FY 2019 Cycle 1.

There were no questions for Dr. Garcia.

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the Prevention Program's plan for proposed RFAs for FY 2019 Cycle 1.

Communications Program Report

Dr. Garcia provided a Communications Program update and reported on program activities (pages 6-5 – 6-42 in the agenda packet). Dr. Garcia gave an overview of the fifth *CPRIT Innovation in Cancer Prevention and Research Conference*, held in November 2017 in Austin. Presiding Officer Montgomery thanked all who were involved with the conference.

Dr. Garcia responded to an Oversight Committee member's question about the number of product development research conference attendees, explaining that the number of people attending

typically reflects the overall percentage of grantees in each CPRIT program. Although CPRIT does not limit the conference to CPRIT grantees; a minority of the attendees were not CPRIT grantees.

Chief Product Development Officer Report, and Request for Applications FY 2019 – Agenda Item 10 – Tab 7

Presiding Officer Montgomery recognized Mr. Lang to present the product development research program report. Mr. Lang directed members to his report in the agenda packet. He noted that the FY 2018.1 Product Development award cycle is complete. The Product Development Review Council, after considering 18 applications, including two applications that completed due diligence, declined to recommend any product development research awards for the first cycle of FY 2018.

Mr. Lang provided an overview of planned future award cycles. He indicated that the product development research program plans to maintain its existing schedule of two award cycles per year through 2021. He expects to release the RFAs for FY 2019.1 in June 2018.

Mr. Lang delivered a power point presentation (in the agenda packet beginning at 7-3) about the Product Development Research Program's new Seed Award RFA, which CPRIT plans to release for the first award cycle in FY 2019.

Responding to an Oversight Committee member's question about how an applicant like Asuragen fits within the range of development stages funded by CPRIT, Mr. Lang explained that Asuragen was early in the development process at the time of the award of 2012.

An Oversight Committee member asked about CPRIT's due diligence process. Mr. Lang explained that CPRIT's peer reviewers have domain expertise and are rigorous in their application evaluations. Mr. Roberts noted that he is concerned with the recent number of projects that go through the due diligence process that are not recommended for an award by the Product Development Review Council. Mr. Roberts indicated that he has engaged the Product Development Review Council to seek ideas to improve the success rates of product development research applicants.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the Product Development Research Program's plan for the proposed RFAs for FY 2019.

Recess

Presiding Officer Montgomery recessed the Oversight Committee for ten minutes at 12:02 p.m.

Reconvene

Presiding Officer Montgomery reconvened the Oversight Committee at 12:13 p.m.

Presiding Officer Montgomery announced that the Oversight Committee would take up Agenda Items 12 and 13 out of agenda order.

University Advisory Committee Annual Report – Agenda Item 12 – Tab 9

Dr. Willson introduced Dr. Michelle Barton, Chair of the University Advisory Committee (UAC). Dr. Barton is a professor at The University of Texas MD Anderson Cancer Center, Department of Epigenetics and Molecular Carcinogenesis, and is the Dean at the Graduate School of Biomedical Sciences partnered with MD Anderson and the UT Health Science Center in Houston. Dr. Willson noted that Dr. Barton has provided outstanding guidance and support to CPRIT through her membership and leadership of the UAC.

Dr. Barton presented the UAC's 2017 annual report and recommendations to the Oversight Committee (pages 9-1 – 9-24 in the agenda packet) and provided an overview of the UAC's mission.

In response to an Oversight Committee member's question about the number of National Cancer Institute (NCI) designated centers in other states, Dr. Barton referred the Oversight Committee to the NCI map for that information.

Dr. Barton noted that prior to CPRIT, The University of Texas MD Anderson Cancer Center was the only NCI-designated Comprehensive Cancer Center in Texas. She credited CPRIT with helping two additional centers, Baylor College of Medicine and The University Texas Southwestern Medical Center, receive Comprehensive Cancer Center status. An Oversight Committee member asked how CPRIT's support for these two new centers made them successful NCI designated centers candidates. Dr. Barton explained that CPRIT's grants have brought increased interest, attention, and other extramural funding to cancer research at these institutions and across the state. Dr. Barton added that CPRIT's recruitment awards, research training awards and core facility support awards are paving the way of the future for Texas.

An Oversight Committee member asked about the number of patients in clinical trials supported by CPRIT grants. Dr. Barton explained that it may be possible to get this information by researching the clinical trial registry. Mr. Roberts added that CPRIT does track the number of patients in clinical trials, explaining that it is a critical metric for CPRIT.

Dr. Barton stated the UAC is supportive of all the RFAs and Program Priorities for FY 2018-2019.

Internal Auditor Report – Agenda Item 13 – Tab 10

Presiding Officer Montgomery recognized Ms. Alyssa Martin, CPRIT Internal Auditor from Weaver and Tidwell, LLP, to present a status update on the FY 2018 internal audit plan, the recent internal audit reports, and the reports on follow-up procedures. She directed members to the audit materials in the meeting packet at pages 10-1 – 10-42 and provided her report.

There were no questions for Ms. Martin.

MOTION:

On a motion made by Dr. Patel and seconded by Mr. Margo, the Oversight Committee unanimously approves the revised FY 2018 audit plan and the internal audit reports and follow up procedures reports as presented by CPRIT's Internal Auditor.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 11 – Tab 8

Presiding Officer Montgomery recognized Mr. Roberts to present the seven appointees to CPRIT's Scientific Research and Prevention Program Committee. Mr. Roberts recommends the appointments to the peer review committees for Oversight Committee approval. He noted that CPRIT provided the biographical information for the seven appointees in the agenda packet (pages 8-5 - 8-64) and that the Nominations Subcommittee discussed the appointments at their February 16, 2018, subcommittee meeting and recommends approval.

There were no questions for Mr. Roberts.

MOTION:

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the seven Scientific Research and Prevention Program Committee appointments.

Recess

Presiding Officer Montgomery recessed the Oversight Committee for a 30-minute recess at 12:44 p.m.

Reconvene

Presiding Officer Montgomery reconvened the Oversight Committee at 1:17 p.m.

Fiscal Year 2020 -2023 Budget Scenarios – Agenda Item 14 – Tab 11

Presiding Officer Montgomery recognized Mr. Roberts to present the FY 2020 – 2023 budget scenarios. Mr. Roberts reported that he discussed the funding scenario preferred by the Oversight Committee at its special meeting in January with an initial group of legislators familiar with CPRIT, as well as CPRIT grantees and cancer advocates. He indicated that he also raised the possibility of CPRIT requesting an estimated \$190 million exceptional item request for the 2020 – 2021 fiscal biennium to maintain current grant funding levels. Mr. Roberts recommends the Oversight Committee approve the preferred funding scenario and the exceptional item request.

There were no questions for Mr. Roberts.

MOTION:

On a motion by Mr. Margo and seconded by Mr. Rice, the Oversight Committee unanimously voted to adopt Budget Scenario 4 for planning purposes, including drafting the agency's request for legislative appropriations for the fiscal biennium beginning September 1, 2019, and to instruct CPRIT staff to prepare an exceptional item request for general revenue funding in an amount to continue current grant levels in the FY 2020 – 2021 biennium, estimated to be \$190 million.

Amendments to 25 TAC Chapters 701 and 703 – Agenda Item 15 – Tab 12

Presiding Officer Montgomery recognized Ms. Cameron Eckel, Staff Attorney, to present the rules changes for Oversight Committee action. Ms. Eckel referred members to the final rule changes and proposed amendments in the Oversight Committee packet at pages 12-1 – 12-17. She reported that the Board Governance subcommittee recommended final approval for amendments to Texas Administrative Code Chapters 701 and 703, originally considered by the Oversight Committee at the November 2017 meeting. In addition, Ms. Eckel reported that the Board Governance subcommittee recommended approval to publish two proposed rule changes to Texas Administrative Code Chapter 703 in the *Texas Register* for public comment.

There were no questions for Ms. Eckel.

MOTION:

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the final orders adopting rules changes to the Texas Administrative Code Chapters 701 and 703 and to approve the publication of the proposed changes to the Texas Administrative Code Chapter 703 in the *Texas Register*.

Chief Operating Officer Report – Agenda Item 16 – Tab 13

Presiding Officer Montgomery called upon Ms. Heidi McConnell, Chief Operating Officer, to present the Chief Operating Officer's report. Ms. McConnell reported on the operating budget, performance measures, and debt issuance history, noting that the information is in the agenda packet at 13-1 – 13-20.

There were no questions for Ms. McConnell.

Subcommittee Business – Agenda Item 17 – Tab 14

Presiding Officer Montgomery laid out agenda item 17, reminding members that at the January meeting the Oversight Committee discussed the need for a new Special Issues subcommittee to address issues, including legislative matters, as they arise. CPRIT staff drafted a Special Issues Subcommittee charter for members' consideration. Presiding Officer Montgomery noted that currently CPRIT's Board Governance Subcommittee is responsible for reviewing legislation affecting CPRIT. He explained that if the Oversight Committee approves the proposed Special Issues Subcommittee charter, the Oversight Committee should revise the Board Governance Subcommittee charter to avoid overlapping duties. He reported that the Board Governance Subcommittee recommended the Oversight Committee approve establishing the Special Issues Subcommittee and changes to the Board Governance Subcommittee duties.

There were no questions for Presiding Officer Montgomery.

MOTION:

On a motion by Mr. Angelou and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the creation of the Special Issues Subcommittee of the Oversight Committee and to ratify its charter.

MOTION:

On a motion by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the proposed changes to the Board Governance Subcommittee charter.

Presiding Officer Montgomery proposed appointing Oversight Committee members Dr. Rice, Mr. Margo, and himself to the Special Issues Subcommittee.

There were no questions.

MOTION:

On a motion made by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the members of the new Special Issues Subcommittee.

Fiscal Year Calendar 2019 – Agenda Item 18 – Tab 15

Presiding Officer Montgomery noted that the regularly scheduled Oversight Committee meeting date in November falls one day before the Thanksgiving holiday. Mr. Roberts indicated that he will propose a new date for the November meeting for consideration at the May Oversight Committee meeting.

Consult with General Counsel – Agenda Item 19

There was no discussion or action on this standing agenda item.

Future Meeting Dates

Presiding Officer Montgomery reported that the next regular Oversight Committee meeting will be May 16, 2018.



Adjourn

MOTION:

There being no further business, the Oversight Committee unanimously approved a motion to adjourn by Presiding Officer Montgomery and seconded by Mr. Angelou.

Meeting adjourned at 1:28 p.m.

Approval of the February 21, 2018 Oversight Committee Minutes:

	5/16/18
Signature	Date
	5/16/18
Signature	Date



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cory M. Mitchell

W. R. Roberts
2/21/18

February 7, 2018

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 57 grant applications totaling \$73,300,770. The PIC recommendations for 49 academic research grant awards and 8 prevention awards are attached.

Dr. Jim Willson, CPRIT's Chief Scientific Officer, and Dr. Becky Garcia, CPRIT's Chief Prevention Officer, have prepared overviews of the academic research and prevention slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all of the information considered by the Review Councils is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on February 21, 2018. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Willson, and Dr. Garcia are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas. Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts
Chief Executive Officer

Academic Research Award Recommendations –

The PIC unanimously recommends approval of 49 academic research grant proposals totaling \$60,195,197. The recommended grant proposals were submitted in response to seven grant mechanisms: Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Biology; Individual Investigator Research Awards for Prevention and Early Detection; Individual Investigator Research Awards for Clinical Translation; Recruitment of First-Time, Tenure-Track Faculty Members; and Recruitment of Rising Stars. The SRC provided the prioritized list of recommendations for the Recruitment awards to the presiding officers on January 19, 2018. One application, RP180261, recommended by the SRC was withdrawn by the applicant prior to the PIC meeting; therefore, the PIC did not consider the application.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state;
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources; and
- address the goals of the Texas Cancer Plan.

Academic Research Grant Award Recommendations

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
1	RP180313	IIRA	1.0	A somatic mutant p53 mouse model of metastatic triple negative breast cancer	Lozano, G.	The University of Texas M. D. Anderson Cancer Center	\$900,000
2	RP180505	IIRAP	1.4	Circulating Exosomes as Biomarkers for Lung Cancer Early Detection	Taguchi, A.	The University of Texas M. D. Anderson Cancer Center	\$799,085
3	RP180147	IIRA	1.6	Prevalence of Rare Passenger Mutations in Biopsy Tissue as Cancer Stratification Markers	Zhang, D.	Rice University	\$900,000
4	RP180047	IIRA	1.7	A Novel Dual Suppressor of Cancer Bone Metastasis	Wan, Y.	The University of Texas Southwestern Medical Center	\$898,672
5	RP180192	IIRA	1.8	Dissecting the interplay between BAP1 and PBRM1 in renal cancer	Brugarolas, J.	The University of Texas Southwestern Medical Center	\$897,633
6	RP180343	IIRA	1.8	Turn ON the Tumor Contrast in Lymph Node Metastases for Occult Disease Detection	Gao, J.	The University of Texas Southwestern Medical Center	\$885,684
7	RP180178	IIRA	1.8	Imaging glucose stimulated zinc secretion (GSZS) from the prostate by MRI: A potentially powerful method	Sherry, D.	The University of Texas Southwestern Medical Center	\$900,000

PIC Recommendation
 FY2018 (February)

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
				for early detection of prostate cancer			
8	RP180463	IIRACCA	1.9	Compound heterozygous mutations in pediatric cancer predisposition	Schlacher, K.	The University of Texas M. D. Anderson Cancer Center	\$556,763
9	RP180248	IIRACB	1.9	Characterizing cancer genome instability and translational impact using new sequencing technologies	Chen, K.	The University of Texas M. D. Anderson Cancer Center	\$898,997
10	RP180191	IIRACCA	1.9	Understanding TFE3-mediated Tumorigenesis through Analysis of a Novel, Clinically-Relevant Mouse Model of Translocation Renal Cell Carcinoma	Brugarolas, J.	The University of Texas Southwestern Medical Center	\$1,155,128
11	RP180220	IIRA	1.9	Targeting the prion protein Doppel in brain tumor angiogenesis	McCarty, J.	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP180435	IIRA	2.0	Fasting-induced inhibition of leukemia development	Zhang, C.	The University of Texas Southwestern Medical Center	\$900,000
13	RP180275	IIRA	2.0	Targeting Stromal ERalpha for Cervical Cancer Therapy	Chung, S.	University of Houston	\$811,617
14	RP180381	IIRACT	2.0	Mass Spectrometry Imaging to Uncover Predictive Metabolic Markers of Ovarian Cancer	Schiavinato Eberlin, L.	The University of Texas at Austin	\$1,092,048

PIC Recommendation
 FY2018 (February)

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
				Surgical Outcome and Treatment Response			
15	RP180394	IIRACCA	2.0	Targeting the metastatic sarcoma niche using leukocyte biomimetic nanoparticles	Tasciotti, E.	The Methodist Hospital Research Institute	\$1,199,617
16	RP180131	IIRACCA	2.1	DNA methylation signatures of cell-free DNA in CSF as a new response biomarker for pediatric medulloblastoma	Sun, D.	Texas A&M University System Health Science Center	\$1,200,000
17	RP180196	IIRACCA	2.1	Microwafers as Novel Drug or Gene Delivery Vehicles for Noninvasive Treatment of Retinoblastoma	Hurwitz, R.	Baylor College of Medicine	\$1,195,721
18	RP180410	IIRA	2.2	Mechanisms of Nuclear Export in Cancer	Chook, Y.	The University of Texas Southwestern Medical Center	\$900,000
19	RP180181	IIRA	2.2	Targeting neutrophil elastase as a novel therapy for metastatic breast cancer	Watowich, S.	The University of Texas M. D. Anderson Cancer Center	\$900,000
20	RP180504	IIRA	2.2	Elucidating the Epigenetic and Metabolic Vulnerabilities of Myeloproliferative Neoplasms	Xu, J.	The University of Texas Southwestern Medical Center	\$900,000
21	RP180268	IIRA	2.2	Determining the role of polyploidization in liver cancer development	Zhu, H.	The University of Texas Southwestern Medical Center	\$900,000

PIC Recommendation
 FY2018 (February)

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
22	RP180309	IIRA	2.2	Inhibiting Oxidative Phosphorylation: A Novel Strategy in Leukemia	Konopleva, M.	The University of Texas M. D. Anderson Cancer Center	\$900,000
24	RP180473	IIRACT	2.2	Clinical trials of C188-9, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with hepatocellular carcinoma (HCC)	Tweardy, D.	The University of Texas M. D. Anderson Cancer Center	\$2,399,905
25	RP180031	IIRA	2.2	Imaging of biochemical alterations in human breast malignancy using CEST-MRI	Vinogradov, E.	The University of Texas Southwestern Medical Center	\$900,000
26	RP180244	IIRA	2.3	Functional analyses of linkage-specific ubiquitination in the DNA damage response	Wang, B.	The University of Texas M. D. Anderson Cancer Center	\$900,000
27	RP180404	IIRACT	2.3	Noninvasive detection of anthracycline induced cardiotoxicity using hyperpolarized carbon 13 based magnetic resonance spectroscopic imaging	Zaha, V.	The University of Texas Southwestern Medical Center	\$2,397,204
28	RP180349	IIRA	2.4	Therapeutics Targeting Cancer-Associated HPV Replication	Chiang, C.	The University of Texas Southwestern Medical Center	\$900,000

PIC Recommendation
 FY2018 (February)

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
29	RP180530	IIRA	2.4	Hippo signaling in non-alcoholic fatty liver disease (NAFLD) and its progression to hepatocellular carcinoma	Johnson, R.	The University of Texas M. D. Anderson Cancer Center	\$821,669
30	RP180607	IIRAP	2.4	Blood-based biomarkers for the early detection of pancreatic cancer	Killary, A.	The University of Texas M. D. Anderson Cancer Center	\$900,000
31	RP180590	IIRA	2.4	Development of an engineered & pharmacologically optimized human methionine-gamma-lyase drug candidate for the treatment of prostate cancer and glioblastoma	Stone, E.	The University of Texas at Austin	\$900,000
32	RP180553	IIRA	2.5	Structural and Functional Characterization of the DNA Double Strand Break Processing Complex of Mre11-Rad50	Latham, M.	Texas Tech University	\$850,876
33	RP180259	IIRA	2.5	PTEN Promotes Diabetic breast cancer metastasis	LIN, C.	The University of Texas M. D. Anderson Cancer Center	\$900,000
34	RP180588	IIRAP	2.5	Novel Computer Aided Diagnosis System For Early Detection Of Oral Cancer Based On Quantitative Autofluorescence Imaging	Jo, J.	Texas Engineering Experiment Station	\$897,394

PIC Recommendation
 FY2018 (February)

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
35	RP180166	IIRACCA	2.6	Molecular mechanisms of anthracycline response in cardiomyocytes and link to genetic susceptibility to cardiotoxicity in long-term childhood cancer survivors	Hildebrandt, M.	The University of Texas M. D. Anderson Cancer Center	\$1,194,520
36	RP180466	IIRACT	2.6	Integrated single-cell biomarkers of T-cell efficacy	Varadarajan, N.	University of Houston	\$1,173,420
37	RP180055	IIRA	2.7	Mechanisms and Treatment of Hippocampal Cognitive Impairment Associated with Androgen Deprivation Therapy for Prostate Cancer	Morilak, D.	The University of Texas Health Science Center at San Antonio	\$899,547
38	RP180472	IIRA	2.8	Mucosal vaccine formulations for targeted therapy of HPV cancers	Sastry, J.	The University of Texas M. D. Anderson Cancer Center	\$883,146
39	RP180457	IIRA	2.8	Tumor Activated Enzyme Inhibitors for the Treatment of Cancer	Ready, J.	The University of Texas Southwestern Medical Center	\$898,776
40	RP180140	IIRACT	2.8	EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial to assess local control of oligometastatic disease	Tang, C.	The University of Texas M. D. Anderson Cancer Center	\$2,394,412

PIC Recommendation
 FY2018 (February)

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Budget
41	RP180634	IIRACCA	2.9	Understanding metabolic regulation of pediatric glioma through mouse modeling and patient tumor interrogation in vivo.	Bachoo, R.	The University of Texas Southwestern Medical Center	\$1,200,000
42	RP180073	IIRACCA	3.4	Myeloid support of refractory and aggressive T-ALL at distinct tumor sites	Ehrlich, L.	The University of Texas at Austin	\$1,200,000
43	RP180177	IIRA	3.5	Novel Small Molecule Probes Targeting Histone Acetyltransferase p300/CBP	Song, Y.	Baylor College of Medicine	\$900,000
44	RP180288	IIRA	3.5	Innate Immune Regulation of Cancer Cell Proliferation	Yan, N.	The University of Texas Southwestern Medical Center	\$900,000
45	RP180319	IIRACCA	3.5	Rhabdomyosarcoma vulnerabilities: Prioritizing and extending to the clinic	Skapek, S.	The University of Texas Southwestern Medical Center	\$1,193,363

IIRA: Individual Investigator Research Awards;

IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents;

IIRACB: Individual Investigator Research Awards for Computational Biology;

IIRAP: Individual Investigator Research Awards for Prevention and Early Detection;

IIRACT: Individual Investigator Research Awards for Clinical Translation

Academic Research Recruitment Grant Award Recommendations

Rank	App ID	Candidate	Mechanism	Organization	Budget	Overall Score
1	RR180011	Bose, Rohit	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
2	RR180014	Zhong, Zhenyu	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
3	RR180017	Jiang, Wen	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
4	RR180016	Hoshida, Yujin	RRS	The University of Texas Southwestern Medical Center	\$4,000,000	2.0
5	RR180012	Jian, Xiaoqian	RRS	The University of Texas Health Science Center at Houston	\$4,000,000	2.8

RRS: Recruitment of Rising Stars

RFTFM: Recruitment of First-Time Tenure Track Faculty Members

Prevention Award Recommendations –

The PIC unanimously recommends approval of eight prevention grant proposals totaling \$13,105,573. The recommended grant proposals were submitted in response to the following mechanisms: Evidence Based Cancer Prevention Services; Tobacco Control and Lung Cancer Screening; Colorectal Cancer Prevention Coalition; and Dissemination of CPRIT-Funded Cancer Control Interventions. The Prevention Review Council (PRC) provided its recommendation to the presiding officers on January 19, 2019.

I will note that two awards are recommended from cycle 17.2. The PRC took no action on the awards previously and recommended them for funding at their meeting on January 18, 2018. The PIC unanimously recommends the two awards to the Oversight Committee.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development proposals met the following CPRIT funding priorities:

- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional (the PIC chose this factor for Established Company Awards);
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state; and
- address the goals of the Texas Cancer Plan.

Prevention Grant Award Recommendations

App. ID	Mech.	Application Title	PD	Organization	Score	Rank Order	Budget
PP170121	EBP	Evidence-Based Hepatocellular Cancer Prevention through Targeted Hepatitis C Screening and Navigation	Jain, Mamta	The University of Texas Southwestern Medical Center	1.3	1	\$1,300,994
PP180003	EBP	BEST 2: Breast Cancer Education Screening and Navigation (BEST) Program for El Paso and West Texas	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	1.7	2	\$1,499,908
PP180031	EBP	Get FIT to Stay Fit. Stepping Up to Fight Colorectal Cancer in the Panhandle.	Obokhare , Izi D	Texas Tech University Health Sciences Center	1.8	3	\$1,498,476
PP180016	TCL	Equitable Access to Lung Cancer Screening and Smoking Cessation Treatment: A Comprehensive Primary Care and Community Health Approach	Zoorob, Roger	Baylor College of Medicine	2	4	\$1,472,918
PP170078	CRC	Alliance for Colorectal Cancer Testing 2.0 (ACT 2.0)	Foxhall, Lewis E	The University of Texas M. D. Anderson Cancer Center	3.1	5	\$4,034,507
PP180025	TCL	Lung Cancer Screening and Patient Navigation (LSPAN)	Argenbright, Keith E	The University of Texas Southwestern Medical Center	3.3	6	\$1,499,997
PP180037	EBP	Advancing an Established Colorectal Cancer Prevention Program for Rural and Underserved Texans through A&M's Family Medicine Residency	McClellan, David A	Texas A&M University System Health Science Center	3.3	7	\$1,499,202

PIC Recommendation
 FY2018 (February)

App. ID	Mech.	Application Title	PD	Organization	Score	Rank Order	Budget
PP180065	DI	Disseminating Cancer Control Framework and Strategies, a UT System Partnership	Argenbright, Keith	The University of Texas Southwestern Medical Center	2.3	1	\$299,571

EBP: Evidence Based Cancer Prevention Services

TCL: Tobacco Control and Lung Cancer Screening

CRC: Colorectal Cancer Prevention Coalition

DI: Dissemination of CPRIT-Funded Cancer Control Interventions



2/21/18



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

WITNESS REGISTRATION CARD

If you intend to testify/comment before the Committee, please complete and sign this form and submit it to CPRIT staff. If you have written testimony, please give CPRIT staff 11 copies to distribute to members, plus one for a file copy.

Testimony/Comment on: CPRIT RENEWAL Pro Con Neutral

JASON CHILTON
Name (please print)
2100 PIPERS FIELD DR.
Mailing Address
Representing

AUSTIN, TX 78758
Title
2/21/18
City, State, Zip
[Signature]
Signature & Date

Please check one:
 Oral Testimony
 Written Testimony Only
 Resource Witness (Available to answer questions)
 No Testimony. Register support or opposition as indicated above.



2/21/18



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

WITNESS REGISTRATION CARD

If you intend to testify/comment before the Committee, please complete and sign this form and submit it to CPRIT staff. If you have written testimony, please give CPRIT staff 11 copies to distribute to members, plus one for a file copy.

Testimony/Comment on: CPRIT Legislative Approv. Request Pro Con Neutral

Robert Sartin
Name (please print)
10412 Ember Glen Dr
Mailing Address
Self
Representing

Austin, TX 78726
Title
[Signature]
City, State, Zip
FEB 21, 2018
Signature & Date

Please check one:
 Oral Testimony
 Written Testimony Only
 Resource Witness (Available to answer questions)
 No Testimony. Register support or opposition as indicated above.

2/21/18



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

WITNESS REGISTRATION CARD

If you intend to testify/comment before the Committee, please complete and sign this form and submit it to CPRIT staff. If you have written testimony, please give CPRIT staff 11 copies to distribute to members, plus one for a file copy.

Testimony/Comment on: CPRIT Legislative Approps Request Pro Con Neutral

Cam Scott
Name (please print)
3 11000 N. MoPac, #100
Mailing Address
American Cancer Society Cancer Action Network
Representing

Sr. Director, Texas Government Relations
Title
Austin, TX 78759
City, State, Zip
CS 2-21-18
Signature & Date

Please check one:

Oral Testimony
 Written Testimony Only

Resource Witness (Available to answer questions)
 No Testimony. Register support or opposition as indicated above.



February 20, 2018

Members of the Oversight Committee
Cancer Prevention & Research Institute of Texas
1701 North Congress Avenue, Suite 6-127
Austin, TX 78701

Dear CPRIT Oversight Committee Members,

Thank you for your continued leadership of the Cancer Prevention & Research Institute of Texas, which has given new hope to cancer patients and their families – and has placed Texas at the forefront of the fight against cancer.

As organizations that are committed to pressing forward in this fight, we are concerned about the projected funding reductions for CPRIT in the next budget cycle and beyond.

As voter-approved bond authority begins to run out in the next biennium, the funds available to continue CPRIT's work will drop precipitously. Not only does this pending funding cliff jeopardize the ongoing work of the groundbreaking research happening in Texas, but it also places at risk the many Texans who are benefitting from lifesaving prevention and early detection services.

We know we don't have to convince you of the importance of the work CPRIT is doing. Where we need your support is in giving Texans the opportunity to have a

debate about whether this work should continue, rather than simply allowing funding to come to an end.

This debate must happen in the next session of the Texas Legislature if we hope to address the pending funding cliff before we reach the bottom.

The ability to secure level funding for CPRIT next session (or to even have the debate in any substantial way) is dependent upon CPRIT's Legislative Appropriations Request (LAR) including an exceptional item to request the difference between the reduced bond-backed amount available and the amount needed to maintain CPRIT's current annual budget of \$300 million.

We consider it imperative that CPRIT include this exceptional item in its LAR, and we urge you to take this necessary action to give advocates the opportunity to earnestly address this issue with lawmakers.

Again, thank you for your lifesaving work on behalf of all Texans, and for your consideration of this request.

On behalf of the Texas Cancer Partnership,

A handwritten signature in black ink that reads "Cam Scott". The signature is written in a cursive, slightly slanted style.

Cam Scott
Senior Director, Government Relations – Texas
American Cancer Society Cancer Action Network
512-573-5356

cc: Wayne Roberts, CEO